Reborne Longevity – Preventive Longevity Hospital in London, UK

Clinic Overview

Reborne Longevity functions as a fully integrated CQC-regulated private hospital at 9 Queen Anne Street, London, W1G 9HW in the Harley Street Medical Area. The hospital is staffed by a multidisciplinary team including cardiologists and specialists spanning metabolic cardiology, regenerative orthopedics, nutrition and functional medicine, male longevity, and regenerative aesthetic medicine.

Three named signature technologies define the clinic's therapeutic infrastructure: IHHT (Intermittent Hypoxia-Hyperoxia Therapy) via Mitovit®, clinical-grade HBOT (up to 2.2 ATA), and clinician-led red light therapy (photobiomodulation) alongside therapeutic plasma exchange (TPE) and Arthrosamid.

Executive Time Efficiency

Reborne’s integrated hospital model reduces the coordination burden typically associated with managing multiple specialists across different institutions.

Diagnostics, specialist consultations, imaging, and therapeutic procedures can be consolidated within a single location. Remote monitoring through research-grade wearables and the Reborne Health App supports continuity between in-clinic visits. Many clients combine this with an executive health check for longevity for deeper insights.

For high-performance individuals operating under sustained cognitive or physical demand, this structure provides centralized oversight rather than episodic consultations.

At a Glance – Reborne Longevity

Marylebone’s central London location supports short, structured visits, particularly for executives already travelling for business. The hospital’s outpatient format allows assessments, imaging, and consultations to be coordinated efficiently within defined appointment windows. You can also explore the best longevity clinics in London to compare similar providers.

🔗 Quick Links

• Clinic Overview
• Why High-Performers Choose Reborne Longevity
• Purpose & Executive Profile
• Medical Philosophy – P4 Medicine & Systems Biology
• Advanced Diagnostics & Medical Assessment
• What Reborne Longevity Does Best
• Before & After – Executive Outcomes
• Signature Longevity & Medical Programs
• Therapies, Facilities & Clinical Infrastructure
• Pricing, Program Structure & Length of Stay
• Plan Your Stay at Reborne Longevity
• Outcomes, Reputation & Professional Recognition
• Executive Perspective
• Frequently Asked Questions

Why High-Performers Choose Reborne Longevity

• Multidisciplinary team: cardiologists and specialists under one roof Reborne's clinical governance is delivered by a multidisciplinary team including cardiologists and specialists spanning metabolic cardiology, regenerative orthopedics, nutrition and functional medicine, male longevity, and regenerative aesthetic medicine. All services operate within a unified CQC-regulated hospital framework at 9 Queen Anne Street, W1G 9HW.
• IHHT Intermittent Hypoxia-Hyperoxia Therapy via Mitovit®: IHHT (Intermittent Hypoxia-Hyperoxia Therapy) delivered via Mitovit® technology is a named, specific therapeutic technology at Reborne Longevity, alternating between oxygen-reduced and oxygen-enriched breathing under clinical supervision to support mitochondrial adaptation, cardiovascular conditioning, and cellular energy efficiency. This is a distinct and named technology not widely available in standard longevity clinics.
• Clinical-grade HBOT: up to 2.2 ATA. Reborne operates clinical-grade Hyperbaric Oxygen Therapy (HBOT) up to 2.2 ATA, a specific, named therapeutic standard reflecting significantly higher pressure than most wellness-grade hyperbaric chambers. Clinical-grade HBOT at this pressure has been studied in research contexts for associations with telomere biology, neurogenesis, and cellular regeneration.
• Clinician-led Red Light Therapy (Photobiomodulation): Clinician-led Red Light Therapy (Photobiomodulation) is a named therapeutic service at Reborne using targeted light wavelengths under clinical supervision to support mitochondrial function, cellular energy production, and tissue recovery. 'Clinician-led' distinguishes this from consumer-grade red-light devices.
• Harley Street Medical Area central: London location: Located at 9 Queen Anne Street, W1G 9HW, within the internationally recognised Harley Street Medical Area one of London's most established private medical districts

Transparent consultation fees: 

• Initial Consultation: £550 (60-minute comprehensive review)
• Follow-up Consultation: £295 (30-minute review)

Purpose & Executive Profile

Reborne Longevity positions its clinical model around healthspan expansion rather than episodic disease treatment. The objective is to identify measurable biological shifts early, before conventional diagnostic thresholds are crossed, and translate findings into structured longitudinal planning.

In England, males spend approximately 61.5 years and females 61.9 years in good health. This measurable gap between lifespan and years lived in optimal functional capacity informs the clinic’s preventive orientation.

The model does not frame aging as reversed or cured. It approaches aging as a modifiable biological process influenced by metabolic, inflammatory, genomic, and behavioral variables. Diagnostics map these variables; they do not determine future outcomes with certainty.

Programs are structured across defined time horizons: 3 months, 6–9 months, and 12+ months, depending on complexity and scope.

Clinical Purpose

Reborne’s clinical intent centers on three structural pillars:

• Early Risk Identification: Moving beyond population “normal ranges” to identify emerging deviations in biomarkers such as HbA1c, inflammatory markers, and lipid parameters before disease thresholds are formally reached.
• System-Level Mapping: Evaluating how metabolic, hormonal, neurological, immune, and gut systems interact rather than isolating symptoms.
• Long-Term Health Governance: Establishing a structured roadmap supported by repeat diagnostics, wearable integration, and defined review intervals.

Population-level research suggests that improving diet quality in midlife is associated with extended life expectancy. Observational studies also show that combining anti-inflammatory dietary patterns with moderate physical activity and adequate sleep correlates with lower all-cause mortality risk.

Who This Clinic Is Designed For

Reborne Longevity is structured for adults operating under sustained cognitive or physical demand who require consolidated oversight rather than fragmented consultations.

Typical profiles include:

• Chief executives and senior corporate leaders
• Founders and entrepreneurs
• Institutional investors
• Professional and endurance athletes
• Individuals managing complex metabolic or inflammatory conditions under physician supervision

Many participants integrate programs into ongoing professional schedules rather than residential stays. The hospital environment supports discretion, coordinated care, and centralized oversight.

Focus Areas

Medical Philosophy – P4 Medicine & Systems Biology

Reborne Longevity applies a P4 Medicine framework, Predictive, Preventive, Personalised, and Participatory, within a regulated hospital environment. The philosophy shifts focus from reactive disease treatment toward earlier biological mapping.

Traditional healthcare models often intervene once diagnostic thresholds are crossed. Reborne’s model seeks to identify measurable deviations before those thresholds are reached, using biomarker panels, genomic sequencing, and biological age analytics.

The clinic integrates Systems Biology principles, viewing the body as a network of interconnected metabolic, hormonal, neurological, immune, and gut systems. Rather than isolating symptoms, interpretation evaluates how system-level interactions influence overall physiological trajectory.

Diagnostics are interpreted under physician supervision. Data dashboards or wearable outputs are not positioned as standalone decision tools.

Predictive & Biological Age Frameworks

Reborne incorporates validated biological age methodologies, including:

• GrimAge epigenetic clock testing
• Klemera–Doubal Method (KDM) biological age modeling
• Phenotypic Age algorithms
• Grip strength as a functional aging biomarker
• VO₂ max as a cardiorespiratory longevity marker

Research suggests that biological age acceleration, particularly through KDM modeling, correlates with increased all-cause mortality risk. In population studies, increases in biological age acceleration have been associated with elevated all-cause mortality risk, though these associations do not determine individual outcomes.

These models are used to contextualize physiological status relative to functional aging markers. They do not determine individual lifespan.

Systems-Level Interpretation

The clinic’s Analytical Center functions as a centralized integration hub. It combines:

• 220+ biomarker panels
• Whole exome sequencing
• Polygenic risk scoring
• Gut microbiome analysis
• Continuous glucose monitoring
• Research-grade wearable tracking (e.g., Oura ring integration)

AI-assisted analysis supports pattern recognition across metabolic, inflammatory, hormonal, and genomic domains.

This approach aims to deeply phenotype an individual’s biological state rather than rely on isolated laboratory results.

Lifestyle as a Clinical Variable

Reborne incorporates nutrigenomics and functional medicine principles into interpretation.

Examples include:

• Tailored dietary guidance based on genetic variants (e.g., MTHFR, APOE, COMT)
• Continuous glucose monitoring to evaluate glycemic variability
• VO₂ max and activity threshold assessment
• Grip strength testing
• Sleep pattern analysis via wearable integration

Research suggests that higher physical activity levels, including ≥ 3000 MET-minutes per week, are associated with deceleration in biological aging markers in certain cohorts. These findings are observational and do not prescribe universal thresholds. Improving sleep quality for recovery is a key part of long-term health strategy.

Advanced Diagnostics & Medical Assessment

Reborne Longevity applies a diagnostics-first architecture designed to establish a multi-system biological baseline before structured planning begins. Assessment precedes strategy. Strategy precedes implementation.

The clinic’s diagnostic framework integrates molecular, metabolic, genomic, and functional data within a hospital-regulated setting. Tools are selected to identify measurable physiological patterns associated with long-term risk trajectories rather than acute symptom management.

No single marker is treated as determinative. Interpretation occurs within a broader systems context under physician supervision.

Diagnostic Assessment Includes

Reborne’s core programs incorporate layered diagnostic depth depending on complexity and program tier.

• Multi-System Biomarker Panels (220+ Markers): Comprehensive laboratory panels assessing inflammatory markers, lipid profiles, hormonal status, glycemic control, metabolic indicators, and organ function metrics.
• Biological Age Analysis: GrimAge, KDM, and Phenotypic Age modeling to contextualize functional aging relative to population benchmarks.
• Whole Exome Sequencing: Genomic sequencing to evaluate inherited risk patterns across multiple disease categories.
• Polygenic Risk Scores: Risk stratification modeling for conditions such as Alzheimer’s disease, coronary artery disease, and other major chronic conditions.
• DEXA Body Composition Analysis: Medical-grade quantification of visceral adipose tissue (VAT), lean mass distribution, and bone density.
• Full-Body MRI (Bespoke Tier): Comprehensive imaging for structural and internal assessment when clinically indicated.
• Fibroscan & Liver Assessment: Evaluation of hepatic fat and fibrosis patterns.
• Continuous Glucose Monitoring (CGM): Two-week glucose variability tracking to assess metabolic flexibility.
• Cardiorespiratory Fitness Testing (VO₂ Max): Measurement of oxygen utilization capacity as a marker associated with functional longevity.
• Grip Strength Testing: Functional strength assessment is linked in research to disability and mortality risk patterns.

Diagnostics are integrated into a 60–80 page personalized health roadmap within flagship programs.

Three-Level Clinical Routing

Reborne applies a structured routing architecture based on complexity.

• Level 1 – Remote Monitoring: Wearable integration (e.g., Oura ring), CGM data, and digital tracking via the Reborne Health App support longitudinal observation between visits.
• Level 2 – In-Clinic Diagnostics & Treatment: Advanced imaging, genomic sequencing, and physician consultations are conducted on-site within the hospital environment.
• Level 3 – Individualised Scientific Studies: For complex or rare conditions, deeper phenotyping and AI-assisted modeling are applied to generate a “digital twin” framework for individualized analysis.

Escalation between levels is determined by clinical complexity rather than standardized packages.

Regenerative & Hospital-Grade Interventions

Where clinically appropriate, Reborne offers advanced procedures delivered within regulated hospital governance.

These may include:

• Therapeutic Plasma Exchange (TPE) – A hospital-based procedure designed to remove inflammatory mediators and pathogenic proteins from plasma. TPE has been studied for its potential role in immune burden reduction and the “peripheral sink” mechanism explored in Alzheimer’s research contexts. It is not positioned as a cure.
• EBO2 Blood Optimization – A medical-grade oxygenation and ozone-based process aimed at supporting immunological balance under supervision.
• Arthrosamid – A non-surgical hydrogel implant used in knee osteoarthritis management, providing long-term joint cushioning in selected cases.

Such interventions are delivered under CQC regulation with specialist oversight. They are not presented as anti-aging reversals or guaranteed disease prevention strategies. Many programs also focus on how to improve immune resilience for longevity.

What Reborne Longevity Does Best

Reborne Longevity differentiates itself through structural integration rather than service breadth. Its strengths lie in consolidation, systems analysis, and regulated delivery within a hospital framework.

The clinic’s positioning centers on reducing fragmentation while increasing diagnostic precision.

Key Medical Strength 1: IHHT via Mitovit® Intermittent Hypoxia-Hyperoxia Therapy

IHHT via Mitovit® technology is a named, exclusive therapeutic capability at Reborne Longevity delivering alternating hypoxic and hyperoxic breathing cycles under clinical supervision to support mitochondrial adaptation, cardiovascular conditioning, and cellular energy metabolism. Applied within structured clinical programs by the multidisciplinary team. 

Key Medical Strength 2: Clinical-Grade HBOT up to 2.2 ATA

Reborne operates clinical-grade Hyperbaric Oxygen Therapy (HBOT) up to 2.2 ATA a named, specific therapeutic standard significantly beyond standard wellness-grade chambers. Delivered within a regulated hospital framework under specialist supervision, HBOT at this pressure reflects clinical rather than consumer-grade oxygen therapy.

Key Medical Strength 3 – Clinician-Led Red Light Therapy (Photobiomodulation)

Clinician-led Red Light Therapy (Photobiomodulation) is a named, supervised therapeutic service applying targeted near-infrared light wavelengths to support mitochondrial function and cellular regeneration, distinct from unsupervised consumer devices through its clinical governance and delivery by the Reborne multidisciplinary team. 

Key Medical Strength 4 – Single-Source Integrated Hospital Model

Reborne's multidisciplinary team,, including cardiologists and specialists, operates within one CQC-regulated facility at 9 Queen Anne Street, W1G 9HW. Primary care, genomics, advanced diagnostics, regenerative therapies (IHHT, HBOT, photobiomodulation, TPE), metabolic cardiology, orthopedics, and surgical capability are centralized under one governance framework. 

Key Medical Strength 5: Analytical Center & Precision Data Translation

220+ biomarkers, whole exome sequencing, polygenic risk scoring, biological age modeling, gut microbiome analysis, CGM, and research-grade wearable data synthesised into a 60–80 page personalized health roadmap under multidisciplinary physician interpretation.

Before & After – Executive Outcomes

The following examples reflect reported experiences and publicly described cases associated with the clinic’s integrated model. They illustrate how structured diagnostics informed clinical planning. They do not represent guaranteed outcomes, and individual results vary.

Outcome 1 – System-Level Identification of Chronic Inflammation

Before:
An individual experiencing persistent bloating and long-standing inflammatory skin symptoms had previously pursued symptom-focused treatments without durable resolution.

After:
Through multi-system assessment, including gut microbiome analysis, inflammatory markers, and metabolic profiling, interpretation focused on internal systemic drivers rather than surface symptoms. A structured plan addressed nutritional, inflammatory, and metabolic contributors under physician supervision.

The reported outcome was improved symptom control and greater clarity regarding root biological contributors.

Source:
Publicly described patient case narratives associated with clinic programs.

Outcome 2 – Elite Athletic Recovery & Monitoring

Before:
An endurance athlete managing sustained training loads sought structured oversight to better understand recovery variability and metabolic strain.

After:
Integration of biological age markers, continuous glucose monitoring, VO₂ max testing, and IV-based recovery protocols enabled longitudinal monitoring under physician oversight.

The reported experience emphasized improved insight into recovery patterns rather than performance enhancement claims.

Source:
Executive and athletic case examples are publicly described in clinic-related materials.

Outcome 3 – Metabolic & Cardiovascular Risk Mapping

Before:
A high-performance executive with no overt symptoms sought preventive assessment.

After:
Comprehensive biomarker panels, DEXA-based visceral fat quantification, and polygenic risk scoring identified early-stage metabolic and cardiovascular risk markers that were not previously tracked.

The outcome centered on awareness and structured planning rather than acute disease treatment.

Source:
Preventive case structures are described within longevity program materials.

Signature Longevity & Medical Programs

Initial Consultation £550 (60-Minute Comprehensive Review)

Entry point into Reborne Longevity.

• 60-minute comprehensive review with the Reborne multidisciplinary team
• Medical history, lifestyle discussion, and program planning
• Discussion of Foundation, Base Camp, or bespoke program pathways
• Overview of named technologies (IHHT via Mitovit®, clinical-grade HBOT, Photobiomodulation)
• £550

Follow-up Consultation £295 (30-Minute Review)

• 30-minute structured review
• Biomarker trend discussion and roadmap adjustment
• £295

Foundation: £4,500 (3 Months)

Baseline multi-system biological assessment:

• 220+ biomarker laboratory panel
• GrimAge biological age testing
• VO₂ max assessment / Grip strength testing
• DEXA body composition analysis
• Physician consultation and structured review
• Access to named therapeutic technologies where clinically indicated (IHHT, HBOT, Photobiomodulation)
• £4,500

Base Camp: £14,500 (6–9 Months)

Expanded genomic and multi-system analysis:

• All Foundation components
• Whole exome sequencing
• Polygenic risk scoring (8+ diseases)
• Gut microbiome analysis / CGM
• Extended physician consultations and structured follow-up
• Named therapeutic technologies integrated throughout the program
• £14,500

Bespoke: £25,000–£50,000+ (12+ Months)

Full-spectrum longitudinal governance:

• Full-body MRI
• Unlimited specialist consultations with the multidisciplinary team
• Priority access to IHHT via Mitovit®, clinical-grade HBOT (2.2 ATA), and Photobiomodulation
• TPE and Arthrosamid where clinically indicated
• Dedicated care coordinator
• AI-assisted deep phenotyping
• £25,000–£50,000+

Therapies, Facilities & Clinical Infrastructure

Reborne Longevity operates from a six-floor Marylebone townhouse functioning as a CQC-regulated private hospital. The facility integrates diagnostics, consultation suites, imaging capability, regenerative procedures, and surgical infrastructure within a single governed environment.

It is not structured as a residential retreat. It functions as an outpatient medical hospital with defined program pathways and specialist oversight.

IHHT Intermittent Hypoxia-Hyperoxia Therapy via Mitovit®

A named, specific therapeutic technology at Reborne Longevity delivered via Mitovit® technology:

• Alternates between hypoxic (low oxygen) and hyperoxic (high oxygen) breathing cycles under clinical supervision
• Supports mitochondrial adaptation, cardiovascular conditioning, and cellular energy efficiency
• Applied within structured clinical programs
• Clinician-supervised delivery, not a consumer wellness device
• Available within appropriate program tiers

Clinical-Grade Hyperbaric Oxygen Therapy (HBOT) up to 2.2 ATA

Named clinical-grade therapeutic capability:

• Pressurised oxygen delivery up to 2.2 ATA clinical-grade specification
• Studied in research contexts for associations with telomere biology, neurogenesis, and cellular regeneration
• Delivered under specialist supervision within CQC-regulated hospital governance
• Distinct from lower-pressure wellness-grade hyperbaric chambers

Clinician-Led Red Light Therapy (Photobiomodulation)

Named, clinician-supervised therapeutic service:

• Targeted near-infrared light wavelengths supporting mitochondrial function and cellular energy
• 'Clinician-led' delivered under clinical supervision as part of structured programs
• Supports tissue recovery, cellular regeneration, and mitochondrial ATP production
• Applied within the Reborne therapeutic framework rather than as a standalone consumer service

Therapeutic Plasma Exchange (TPE)

Hospital-based plasma filtration procedure under specialist oversight:

• Designed to remove inflammatory mediators and circulating proteins
• Studied in immune modulation contexts and Alzheimer's research ('peripheral sink' hypothesis)
• Not positioned as curative delivered within regulated hospital governance

Arthrosamid

Non-surgical hydrogel implant for knee osteoarthritis management:

• Provides long-term joint cushioning in selected cases
• Delivered under specialist orthopaedic supervision within hospital framework

Analytical Center & Data Integration

The clinic’s Analytical Center functions as its central integration hub.

It synthesizes:

• Multi-omic laboratory data
• Genomic sequencing
• Biological age modeling
• Microbiome profiling
• Wearable tracking (e.g., Oura integration)
• Continuous glucose monitoring

AI-assisted systems support pattern recognition across interconnected biological domains.

Data remains physician-interpreted. Machine learning assists integration but does not replace clinical judgment.

Governance, Privacy & Laboratory Standards

Reborne operates under the Care Quality Commission (CQC) regulation. Laboratory samples are processed using anonymized patient reference numbers rather than names.

The clinic partners exclusively with laboratories accredited under standards such as:

• CLIA
• CAP
• ISO 15189

This structure supports genomic privacy, traceability, and institutional accountability.

Pricing, Program Structure & Length of Stay

Reborne Longevity operates within a private hospital model in central London. Pricing reflects diagnostic depth, genomic integration, imaging capability, specialist oversight, and longitudinal monitoring architecture.

Fees are not performance-based and do not guarantee biological outcomes. Suitability and scope are confirmed following intake review and physician assessment.

Pricing

Pricing reflects access to structured medical oversight and hospital-based infrastructure rather than guaranteed outcomes.

Pricing Notes

How Programs Are Structured

All programs follow a defined governance sequence:

1. Pre-Visit Phase

• Digital intake documentation
• Medical history review
• Medication disclosure
• Eligibility screening

2. Diagnostic Phase

• Multi-system laboratory testing
• Imaging (DEXA, MRI, where applicable)
• Genomic sequencing (Base Camp & Bespoke tiers)
• Biological age testing
• Functional assessments (VO₂ max, grip strength)

3. Physician Interpretation Phase

• Cardiovascular risk mapping
• Metabolic and inflammatory analysis
• Genomic contextualization
• Structured discussion of findings

4. Planning & Monitoring Phase

• Written longevity roadmap
• Structured follow-up consultations
• Repeat laboratory testing at defined intervals
• Escalation to advanced procedures where clinically indicated

Evaluation precedes strategy. Strategy precedes implementation. Monitoring occurs at defined intervals. These structured programs are similar to executive longevity testing packages designed for high performers.

Length of Stay

Reborne operates exclusively as an outpatient hospital.

Duration varies by program:

• Foundation: Diagnostic sessions across initial visits within a 3-month period
• Base Camp: Expanded diagnostics and follow-up consultations over 6–9 months
• Bespoke: Longitudinal oversight extending 12 months or longer

There is no mandatory residential admission. Surgical or procedural interventions, when performed, follow standard hospital scheduling protocols.

Appointments are integrated into professional schedules rather than immersive retreats.

Plan Your Stay at Reborne Longevity

Clinic: Reborne Longevity Address: 9 Queen Anne Street, London, W1G 9HW (Harley Street Medical Area) Regulatory Status: CQC-regulated private hospital Team: Multidisciplinary — cardiologists and specialists

Recommended Visit Duration

• Initial Consultation: 60 minutes (£550)
• Follow-up Consultation: 30 minutes (£295)
• Foundation (3 months): Diagnostic sessions across initial visits + follow-up
• Base Camp (6–9 months): Expanded diagnostics + genomic testing + periodic consultations
• Bespoke (12+ months): Ongoing oversight + specialist coordination + advanced imaging

No mandatory residential admission. IHHT, HBOT, and photobiomodulation sessions are integrated within program scheduling.

How to Reach the Clinic

City: London, United Kingdom
Area: Marylebone
Regulatory Status: CQC-regulated private hospital

Nearest Airport: London Heathrow Airport (LHR)

Typical Transfer Time: Approximately 45–60 minutes by car, depending on traffic conditions.

Transport Options:

• Licensed taxi services
• Ride-share platforms
• London Underground
• National rail connections
• Private chauffeur services

🔗 Find best flights to London
🔗 Find car rentals in London

Links are provided for travel planning convenience only.

Accommodation & Stay Planning

Reborne Longevity does not operate on-site accommodation.

Visitors typically stay at:

• Central London business hotels
• Serviced apartments in Marylebone
• Boutique hotels within walking distance

Accommodation arrangements are independent of hospital operations.

🔗 Explore nearby hotels & apartments

What to Bring

Participants are generally advised to bring:

• Government-issued identification
• Prior medical documentation (if available)
• Current medication list
• Comfortable clothing suitable for exercise testing
• Any wearable devices currently used for health tracking

Additional documentation requirements are communicated during intake review.

Outcomes, Reputation & Professional Recognition

Reborne Longevity has been positioned within the emerging longevity medicine sector as a hospital-based, data-integrated model combining diagnostics, genomics, and regenerative medicine under one regulatory structure.

Public discussions surrounding the clinic focus on its multi-omic integration, hospital governance, and emphasis on systemic root-cause evaluation rather than isolated biomarker optimization.

Longevity medicine remains a developing scientific field. Biomarkers often reflect risk associations rather than deterministic outcomes. Observational research dominates much of the discipline due to the impracticality of lifespan-length clinical trials.

Reborne’s positioning emphasizes structure and integration over outcome guarantees.

What Patients Commonly Report

Based on publicly described case narratives and sector commentary, recurring themes include:

• Greater visibility into previously unmeasured biological systems
• Identification of inflammatory or metabolic contributors not addressed in symptom-focused care
• Appreciation for genomic risk contextualization
• Clarity in understanding how multiple systems interact
• Structured follow-up rather than one-time data reporting

Reports frequently highlight the Analytical Center’s ability to consolidate laboratory, genomic, microbiome, and wearable data into a unified interpretation framework.

These experiences reflect subjective accounts. They do not represent guaranteed clinical outcomes.

Professional & Industry Positioning

Reborne Longevity is distinguished by:

• CQC-regulated private hospital status
• Integration of surgical, regenerative, and diagnostic services under one roof
• Use of whole-exome sequencing and polygenic risk scoring
• Inclusion of biological age algorithms (e.g., GrimAge)
• Multi-omic analytical architecture

Sector commentary often references its hospital-based infrastructure as a differentiator from boutique wellness clinics.

Operational scale, technological integration, or media visibility do not equate to validated long-term lifespan outcomes. The broader field of preventive geroscience continues to evolve.

Executive Perspective

Reborne Longevity operates within the evolving field of preventive geroscience, combining hospital-based governance with multi-omic diagnostics and longitudinal monitoring. Its positioning differs from lifestyle-oriented longevity centers by embedding genomic sequencing, advanced imaging, and regenerative procedures within a regulated private hospital framework.

The broader longevity sector remains scientifically transitional. Many biomarkers associated with aging and chronic disease are supported by observational correlations rather than definitive lifespan trials. Biological age algorithms and polygenic risk scores offer probabilistic insight, not deterministic forecasts. Surrogate markers are often used because decades-long outcome studies are impractical.

Within these constraints, Reborne’s model emphasizes structured interpretation over technological novelty. Diagnostics precede strategy. Strategy is reviewed longitudinally. Regenerative procedures are delivered under specialist supervision rather than experimental positioning. This reflects trends seen across the best longevity clinics in Europe.

For executives who approach health as governance rather than episodic repair, the clinic offers system-level visibility and scheduled reassessment within acknowledged scientific limits. The value lies in integration and oversight, not in outcome guarantees.

Frequently Asked Questions

Is Reborne Longevity a medical hospital or a wellness clinic?

Reborne operates as a Care Quality Commission (CQC)-regulated private hospital in central London. It is structured around physician-led diagnostics, genomic sequencing, imaging, and regulated procedures.

It is not positioned as a spa, retreat, or lifestyle optimization center. All assessments and interventions occur within a hospital governance framework.

Who is Reborne Longevity designed for?

The clinic primarily serves executives, founders, investors, professional athletes, and individuals operating under sustained cognitive or performance demand.

It is structured for those seeking systematic biological evaluation, genomic risk modeling, and longitudinal oversight rather than acute disease treatment.

Are programs personalised?

Yes. Interpretation is individualized based on biomarker data, genomic sequencing, imaging findings, medical history, and physician review.

Programs are structured but not protocol-driven without prior assessment. Recommendations follow diagnostic interpretation rather than precede it.

Does Reborne treat chronic diseases such as diabetes, heart disease, or cancer?

Reborne focuses on preventive diagnostics, risk mapping, and regenerative procedures within a hospital setting.

It does not replace specialist disease management programs. Individuals with established medical conditions should continue working with their primary physicians or consultants.

Are genomic and biological age tests definitive?

No. Genomic sequencing and biological age algorithms provide probabilistic insight based on population-level data.

They identify risk associations rather than certainties and must be interpreted within full clinical context.

Is privacy maintained?

Yes. The hospital operates under CQC regulation and established UK medical confidentiality standards.

Laboratory samples are anonymized using reference identifiers. Data handling follows regulated governance procedures.

Can I continue working during the program?

Yes. Reborne functions as an outpatient hospital. Most diagnostics and consultations are appointment-based and can be integrated into existing professional schedules.

Certain procedures may require recovery time consistent with standard medical practice.

Does participation guarantee prevention or lifespan extension?

No. Diagnostics identify measurable physiological patterns at a given time. They do not guarantee disease avoidance, reversal, or extended lifespan.

Longevity medicine remains an evolving field supported largely by observational research.

How should value be evaluated relative to cost?

Evaluation may consider:

• Depth of multi-system biomarker testing (220+ markers)
• Whole exome sequencing and polygenic risk scoring
• Biological age modeling
• Imaging capability including full-body MRI
• Regulated hospital infrastructure
• Longitudinal physician oversight

Pricing reflects diagnostic architecture and clinical governance rather than promised outcomes.

A Strategic Pause That Protects the Years Ahead

High-performance careers rarely decline suddenly. They erode incrementally through compressed recovery cycles, sustained cognitive load, irregular sleep, metabolic drift, and unmeasured inflammation. The effect is rarely visible in a single quarter. It accumulates over the years.

Reborne Longevity positions itself within this long-arc perspective.

Its model does not promise reversal of aging or immunity from disease. Instead, it offers structured visibility into biological systems that often remain unmeasured until symptoms appear. Genomic sequencing, multi-omic biomarker panels, imaging, and biological age modeling are consolidated within a regulated hospital framework and interpreted under physician supervision.

The broader longevity sector continues to evolve. Many biomarkers are associative rather than causative. Polygenic risk scores provide probability ranges, not certainty. Biological age clocks estimate trajectory, not destiny.

Within these constraints, structured oversight may provide clarity.

For executives who approach health as governance rather than episodic repair, the value lies in disciplined evaluation, contextual interpretation, and periodic reassessment. Measurement does not guarantee outcome but the absence of measurement guarantees uncertainty.

Reborne offers structure, not promise.

👉 View Longevity Program
↩ Return to ExtendMy.Life
↑ Back to Top

Disclaimer

This clinic profile is provided for informational and editorial purposes only. It does not constitute medical advice, diagnosis, treatment recommendation, or endorsement. No doctor–patient relationship is created through this content.

Reborne Longevity operates as a CQC-regulated private hospital offering preventive diagnostics, genomic analysis, imaging, and regulated medical procedures under physician supervision. The information presented here describes clinical structure, governance, and publicly referenced service architecture. It is not intended to guide individual healthcare decisions.

Diagnostic tools such as multi-system biomarker panels, whole exome sequencing, polygenic risk scoring, biological age algorithms, full-body MRI, DEXA scanning, continuous glucose monitoring, and regenerative procedures identify measurable physiological or probabilistic risk patterns at a specific point in time. These findings do not predict certainty of disease, guarantee prevention, reverse aging, or determine lifespan.

Longevity medicine is an evolving scientific discipline. Many associations between biomarkers and long-term outcomes are observational rather than causative. Surrogate markers are frequently used because definitive lifespan trials are impractical. Individual biological responses vary based on genetics, medical history, environment, and adherence to physician guidance.

Individuals with chronic conditions, including cardiovascular disease, diabetes, autoimmune disorders, neurological conditions, or active cancer, should consult their personal physician or specialist before participating in any new diagnostic or medical program.

All healthcare decisions should be made in consultation with a qualified licensed medical professional who understands the individual’s complete medical history.

ExtendMy.Life does not guarantee clinical outcomes and assumes no responsibility for medical decisions made based on this informational profile.

References

Benjamin, E.J., Muntner, P., Alonso, A., Bittencourt, M.S., Callaway, C.W., Carson, A.P., Chamberlain, A.M., Chang, A.R., Cheng, S., Das, S.R. and Delling, F.N. (2019) ‘Heart disease and stroke statistics—2019 update: A report from the American Heart Association’, Circulation, 139(10), pp. e56–e528.

Belsky, D.W., Caspi, A., Arseneault, L., et al. (2015) ‘Quantification of biological aging in young adults’, Proceedings of the National Academy of Sciences, 112(30), pp. E4104–E4110.

Franceschi, C. and Campisi, J. (2014) ‘Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases’, The Journals of Gerontology: Series A, 69(Suppl 1), pp. S4–S9.

Horvath, S. (2013) ‘DNA methylation age of human tissues and cell types’, Genome Biology, 14(10), p. R115.

Levine, M.E., Lu, A.T., Quach, A., et al. (2018) ‘An epigenetic biomarker of aging for lifespan and healthspan’, Aging (Albany NY), 10(4), pp. 573–591.

Levine, M.E., Lu, A.T., Chen, B.H., et al. (2019) ‘DNA methylation GrimAge strongly predicts lifespan and healthspan’, Aging (Albany NY), 11(2), pp. 303–327.

Libby, P. (2002) ‘Inflammation in atherosclerosis’, Nature, 420(6917), pp. 868–874.

Loos, R.J.F. (2012) ‘Genetic determinants of common obesity and their value in prediction’, Best Practice & Research Clinical Endocrinology & Metabolism, 26(2), pp. 211–226.

Siegel, R.L., Miller, K.D., Wagle, N.S. and Jemal, A. (2023) ‘Cancer statistics, 2023’, CA: A Cancer Journal for Clinicians, 73(1), pp. 17–48.

Torkamani, A., Wineinger, N.E. and Topol, E.J. (2018) ‘The personal and clinical utility of polygenic risk scores’, Nature Reviews Genetics, 19(9), pp. 581–590.

UK Biobank (2015) UK Biobank: Protocol for a large-scale prospective epidemiological resource. Stockport: UK Biobank.

World Health Organization (2023) World health statistics 2023: Monitoring health for the SDGs. Geneva: World Health Organization.

World Health Organization (2023) Global cancer observatory: Cancer today. Lyon: International Agency for Research on Cancer.